Julia Marx

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

Journal: Haematologica

Published: February 04, 2026

Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Journal: Annals of hematology

Published: January 02, 2026

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Journal: Leukemia research

Published: October 06, 2025

Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in Remission.

Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in Remission.

Journal: Transplantation and cellular therapy

Published: August 20, 2025

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

Journal: Blood advances

Published: May 09, 2025

Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.

Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.

Journal: Bone marrow transplantation

Published: May 02, 2025

High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia-A Retrospective Single-Center Study.

High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia-A Retrospective Single-Center Study.

Journal: Transplantation and cellular therapy

Published: March 19, 2025

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Journal: Transplantation and cellular therapy

Published: December 08, 2024

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia.

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia.

Journal: Blood

Published: September 10, 2024

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.

Journal: British journal of haematology

Published: February 15, 2024

Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.

Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.

Journal: Bone marrow transplantation

Published: February 04, 2024

Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.

Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 26, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026